Wikipedia -WSS

Wikipedia

author：explore 2025-10-02 00:28:33 - browse：24622

FDA's Peter Marks talks with STAT's Adam Feuerstein — Peter Marks, the FDA's top regulator of gene therapies (right), speaks with STAT's Adam Feuerstein in San Francisco. Sarah Gonzalez/Peopletography for STAT

SAN FRANCISCO — Peter Marks, the Food and Drug Administration’s top regulator of gene therapies, seems very comfortable with granting some form of full approval to Elevidys, the Sarepta Therapeutics gene therapy for Duchenne muscular dystrophy, based on his comments to me on Monday night during our “fireside chat” at a STAT event.

To be clear, Marks declined to comment specifically about the ongoing FDA review of Elevidys. I tried. However, Marks described a “hypothetical case” in the context of my Sarepta questions that clearly suggested the failure of an Elevidys confirmatory study in October didn’t bother him all that much.

“Hypothetically, if you had a product that used an aggregate scale and all of the components of that aggregate scale looked pretty good, or nearly all of them look pretty good, but the aggregate, for various reasons, didn’t come out perfectly. We approved products based on that,” Marks told me.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Cuban government calls US nuclear submarine stop a 'provocative escalation'

leisure time

WSS

FDA moves to stop vape shops from selling Elf Bar, Esco Bars

After half a century, Israel moves to evict squatter from his cave home on the beach

Is there an 'orca uprising'? Like orcas themselves, the answer is complex.

Women's World Cup brings attention to abuse in soccer

A public scorecard can help hold safety

Va. Republicans encourage early voting, a target of Trump's, ahead of fall elections

explore

Wikipedia

Wikipedia

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Google and Epic fight stronger regulation of AI in health care

Medical records are filled with copy

Startup Neumora takes a novel depression drug to Phase 3

Anesthesiologist group: stop taking Ozempic before surgery

Detailed data confirm benefits, risks of Eli Lilly's Alzheimer's drug

Drug repurposing or repositioning? The language matters

Companies helping big Covid

Bright Health sells Medicare Advantage business to Molina

Biden tests positive for Covid

focus

Grail's uphill battle for Medicare to cover its cancer screening test

WHO calls for emergency meeting on new China virus, as cases spread

Antibody drugs appear effective. Now can we make enough of them?

The debate over Covid

A public scorecard can help hold safety

Cosmetics set for new safety regulation. Why the industry is on board

entertainment

entertainment

leisure time

leisure time